[1] Bray F,Ferlay J, Soerjomataram I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68:394-424. [2] 卢冬彦. 原发性肝癌伴门脉癌栓与血清肿瘤标志物表达相关[J]. 基础医学与临床,2019,39:1335-1336. [3] Elizabeth Mccracken EK, Samsa GP, Fisher DA,et al. Prognostic significance of primary tumor sidedness in patients undergoing liver resection for metastatic colorectal cancer[J]. HPB(Oxford),2019,21:1667-1675. [4] Hirooka M, Hiraoka A, Ochi H,et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation:outcomes in patients with barcelona clinic liver cancer stage b hepatocellular carcinoma[J]. AJR Am J Roentgenol,2018,210:891-898. [5] 王长青,陈玲,徐萍,等. miR-409-3p在肝癌HepG2细胞中的表达及其在细胞增殖中的作用机制[J]. 临床肝胆病杂志,2023,39:1895-1902. [6] Wang H, Hu X, Yang F. miR-325-3p promotes the proliferation,invasion,and emt of breast cancer cells by directly targeting S100A2[J]. Oncol Res,2021,28:731-744. [7] 施喆,韩艳珍,周丽媛,等. miR-325-3p靶向CLDN1调控人肝癌细胞增殖,侵袭与迁移[J]. 现代消化及介入诊疗,2022,27:852-858. [8] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 传染病信息,2020,33:481-500. [9] 中华医学会肝病学分会. 肝硬化诊治指南 [J]. 中华肝脏病杂志,2019,27:846-865. [10] 张余飞,康静波,温居一,等. RECIST1.1标准和mRECIST标准在原发性肝癌SBRT治疗后疗效评价中的对比研究[J]. 中国肿瘤临床,2016,43:902-906. [11] Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma[J]. Biosci Trends,2021,15:155-160. [12] Li L, Ai R, Yuan X,et al. LINC00886 facilitates hepatocellular carcinoma tumorigenesis by sequestering microRNA-409-3p and microRNA-214-5p[J]. J Hepatocell Carcinoma,2023,10:863-881. [13] Li L,Ji Y,Chen YC,et al. miR-325-3p mediate the CXCL17/CXCR8 axis to regulate angiogenesis in hepato-cellular carcinoma[J]. Cytokine,2021,141:155436-155444. |